leadf
logo-loader
viewGlaxoSmithKline PLC
(
LSE:GSK
)

GlaxoSmithKline: Back to the drawing board for UK drugs giant and French partner in their bid to deliver coronavirus vaccine

It is the first setback in a largely successful quest for a vaccine

GlaxoSmithKline PLC -

GlaxoSmithKline PLC (LON:GSK) said it and French partner Sanofi will have to go back to the drawing board after the coronavirus (COVID-19) vaccine they were developing failed to show a strong enough response in the most at-risk group – the over 50s.

The groups will begin a phase IIb study of an enhanced formulation in February, meaning they won’t have a jab market-ready until the fourth quarter of 2021 (instead of the middle of last year as first planned).

“We have identified the path forward and remain confident and committed to bringing a safe and efficacious COVID-19 vaccine,” said the inaptly named Thomas Triomphe of Sanofi Pasteur.

He described the latest pre-clinical data from a newly-optimised version of the drug, which has been tested in animals, as “encouraging”.

"No single pharma company can make it alone; the world needs more than one vaccine to fight the pandemic," said Triomphe.

It is the first setback in a largely successful quest for a vaccine that has seen breakthroughs from Pfizer/BioNTech, Moderna and Oxford University/AstraZeneca.

The UK this week became the first country in the world to start inoculating its population after giving rapid approval to Pfizer/BioNTech drug.

Mass vaccine roll-out will be aided by the approval of other drugs, particularly the Oxford/AZ drug, which is free of storage challenges faced by the other vaccines.

The failed approach deployed Sanofi’s recombinant DNA strain used normally for flu jabs alongside GSK’s adjuvants, which are designed to enhance the immune response.

Quick facts: GlaxoSmithKline PLC

Follow
LSE:GSK

Price: 1388 GBX

Market Cap: £69.84 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Iofina says 'our business has been strong' reporting record revenue and...

Iofina PLC (AIM:IOF, OTC:IOFNF, FRA:IF7) (AIM:IOF, OTC:IOFNF, FRA:IF7) Tom Becker joins Proactive London to explain what drove their record revenue and profit in the first half.  Debt also fell in the first half of the year despite production outages caused by extreme weather and reduced...

1 day, 4 hours ago

2 min read